Plain-English translation of NCT05168566 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called Sutetinib Maleate to see if it can treat advanced or spreading lung cancer in patients whose tumors have specific uncommon genetic changes (L861Q, G719X, or S768I mutations). Sutetinib works by blocking a protein called EGFR that helps cancer cells grow and survive. Researchers want to find out if this medication is effective and safe for people with these particular genetic forms of lung cancer.
Most lung cancer drugs are designed to target common genetic mutations, but some patients have rarer, uncommon mutations that don't respond well to existing treatments. This trial exists to see whether this new medication can work better for patients with these specific uncommon mutations.
You likely qualify if…
You likely don't qualify if…
You would take Sutetinib capsules by mouth as the sole treatment for your lung cancer. The trial involves visits to the research center where doctors will monitor how well the medication is working through imaging scans and blood tests, and track any side effects you experience. The study is enrolling about 99 patients total, and your specific visit schedule and treatment duration would be discussed with the research team at enrollment.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
United States